Sensei Biotherapeutics (NASDAQ:SNSE), a clinical-stage biotechnology company dedicated to advancing next-generation cancer treatments, today announced its financial results for the full year ended December 31, 2024, alongside key corporate updates.
Sensei reported a net loss of $30.2 million for 2024, an improvement from $34.1 million in 2023, reflecting tighter cost management and operational efficiency.
Research and development (R&D) expenses rose slightly to $18.6 million in 2024 from $18.3 million in 2023, driven by increased clinical trial costs and one-time employee termination benefits.
These increases were largely offset by reductions in preclinical research expenses and consulting fees.
As of December 31, 2024, Sensei’s cash, cash equivalents, and marketable securities totaled $41.3 million, down from $65.8 million at the end of 2023.
The company anticipates that its current cash reserves will sustain operations into Q2 2026.
Elsewhere, Sensei provided an update on its lead candidate, solnerstotug, currently in a Phase 1/2 clinical trial.
Preliminary efficacy data from the dose expansion cohort revealed promising results, including durable responses and tumor shrinkage in patients with PD-(L)1 resistant “hot” tumors—a challenging population with limited treatment options.
Additionally, solnerstotug continues to exhibit a favorable safety and tolerability profile, reinforcing its potential as a next-generation therapeutic.
The company also achieved target enrollment in the dose expansion cohort, a significant milestone in the trial.
Full data from this cohort is expected by the end of 2025, offering further insight into solnerstotug’s efficacy and clinical impact.